Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adamas Pharmaceuticals, Inc.

https://www.adamaspharma.com/

Latest From Adamas Pharmaceuticals, Inc.

Keeping Track: Targeted Oncologics Tepmetko, Ukoniq Cleared; Posimir Earns Opioid-Sparing Language

The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Clinical Trials Coronavirus COVID-19

Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

Deals Business Strategies

Sandoz Will Wait A Decade On Amantadine

Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.

Intellectual Property Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Osmotica Pharmaceutical US
UsernamePublicRestriction

Register